⌕
Ionis Pharmaceuticals · IONS · Nasdaq
Tenet 27 · Weak
Compare
$28.02−3.58%At closeTenet 27 · Weak
$28.02−1.04 (−3.58%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Ionis Pharmaceuticals (IONS) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice
Business engineChoppy: revenue compounds ~3.9%/yr (FY21→FY25), net margin −40.4%. Worth your attention in FY25: Share count (+13.5%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲33.8%
943.7
FY21→FY25CAGR +3.9%/yr
Net income ($M)▲16.0%
−381.4
one-off year: see footnoteCAGR —
Free cash flow ($M)▲41.4%
−320.0
FY21→FY25CAGR —
Diluted EPS▲21.7%
−2.38
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+13.5%

141.0mn → 160.0mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.

Capex
$51.4M

steady at 5.5% of revenue (+13.6% YoY).

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)943.7Revenue−15.9COGS927.8Gross profit−915.6R&D−393.9SG&A−381.7Op income0.3Tax & other−381.4Net income

-40¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.

Margin trend · direction beats level Gross Operating Net
1007550250%sector median net margin ~4%FY21FY25

Over this window: gross 98.7% → 98.3%. Net margin -40.4% is below the sector median.

The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
960,092.0943,711.0705,138.0787,647.0587,367.0810,456.0▲33.8%+3.9%
Cost of revenue
17,001.015,909.011,215.09,133.014,116.010,842.0▲41.9%+10.1%
Gross profit
943,091.0927,802.0693,923.0778,514.0573,251.0799,614.0▲33.7%+3.8%
Research & development
922,804.0915,619.0901,530.0899,625.0833,147.0643,453.0▲1.6%+9.2%
Selling, general & admin
585,163.0393,867.0267,474.0232,619.0150,295.0186,347.0▲47.3%+20.6%
Total operating expenses
1,507,967.01,309,486.01,169,004.01,132,244.0983,442.0829,800.0▲12.0%+12.1%
Operating incomefeeds ROC rank
−564,876.0−381,684.0−475,081.0−353,730.0−410,191.0−30,186.0▲19.7%—
Other income, net
21,155.02,083.015,013.019,765.0152,206.01,038.0——
Pretax income
−543,721.0−379,601.0−460,068.0−333,965.0−257,985.0−29,148.0▲17.5%—
Income tax
2,818.01,786.0−6,171.032,321.011,737.0−551.0—−46.6% (22→25)
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−546,539.0−381,387.0−453,897.0−366,286.0−269,722.0−28,597.0▲16.0%—
Per share
Diluted EPSbuyback-sensitive
−3.26−2.38−3.04−2.56−1.90−0.20▲21.7%—
Diluted shares (mn)
166.21160.01149.51143.19141.85141.02▲7.0%+3.2%
Margins
Gross margin95th pct in Healthcare
98.2%98.3%98.4%98.8%97.6%98.7%▼0.1pp−0.3pp
Operating margin
−58.8%−40.4%−67.4%−44.9%−69.8%−3.7%▲26.9pp−36.7pp
Net margin14th pct in Healthcare
−56.9%−40.4%−64.4%−46.5%−45.9%−3.5%▲24.0pp−36.9pp
† TTM = trailing four quarters through 2026-09-30.FY23 effective tax rate was −10% vs a −0% norm for this window, likely a one-time item; see the filing.
FY08 – FY20 · 13 more years
Unlock the full history →
5 more years of statements and CSV export are on Premium, and 13 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-02-26 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Ionis Pharmaceuticals' revenue last fiscal year?

Ionis Pharmaceuticals reported revenue of $943.7M in fiscal 2025, up 33.8% from fiscal 2024.

What was Ionis Pharmaceuticals' net income?

Ionis Pharmaceuticals reported net income of −$381.4M in fiscal 2025, a net margin of −40.4%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.